journal
MENU ▼
Read by QxMD icon Read
search

Journal of Ocular Pharmacology and Therapeutics

journal
https://read.qxmd.com/read/30758244/evaluation-of-antiglaucomatous-drops-on-conjunctival-thickness-in-patients-with-primary-open-angle-glaucoma
#1
Serek Tekin, Erbil Seven, Muhammed Batur
PURPOSE: To determine the effects of antiglaucomatous drops on the conjunctival thickness. METHODS: Between March 2018 and May 2018, conjunctival thicknesses (epithelium + stroma) were measured with anterior segment OCT in 51 eyes of the control group and 49 eyes who had glaucoma diagnosis at the Van YYU Medical Faculty Ophthalmology Department and had been using antiglaucomatous drops for at least 6 months. At 12 o'clock direction, horizontal multisections were taken aiming at the conjunctiva 3-5 mm away from the limbus...
February 13, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30698494/dose-response-of-intracameral-bimatoprost-sustained-release-implant-and-topical-bimatoprost-in-lowering-intraocular-pressure
#2
Susan S Lee, Mohammed Dibas, Alexandra Almazan, Michael R Robinson
PURPOSE: To compare the dose-response profiles of bimatoprost sustained-release implant (Bimatoprost SR) and topical bimatoprost in lowering intraocular pressure (IOP) in normotensive beagle dogs. METHODS: In 1 study, topical bimatoprost 0.001%, 0.01%, or 0.1% was administered twice daily in the study eye for 5 days. IOP was measured at baseline and up to hour 6 each day. Other studies evaluated the IOP response to a single administration of Bimatoprost SR at dose strengths ranging from 8 to 120 μg...
January 30, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30688558/analgesic-effect-of-a-single-drop-of-nepafenac-0-3-on-pain-associated-with-intravitreal-injections-a-randomized-clinical-trial
#3
Constantine D Georgakopoulos, Panagiotis Plotas, Konstantinos Kagkelaris, Foteini Tsapardoni, Olga E Makri
PURPOSE: To evaluate the analgesic effect of nepafenac 0.3% in patients undergoing intravitreal injections (IVI) of antivascular endothelial growth factors. METHODS: This is a single-center, prospective, randomized, blinded, triple-arm, placebo-controlled interventional study. Patients were randomized into 3 Groups. Group 1 (n = 33) received nepafenac 0.1%, Group 2 (n = 32) received nepafenac 0.3%, and Group 3 (n = 31) received placebo 40 min before IVI...
January 28, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30688548/gene-therapy-for-inherited-retinal-degeneration
#4
Amirmohsen Arbabi, Amelia Liu, Hossein Ameri
Inherited retinal degeneration (IRD), a group of rare retinal diseases that primarily lead to the progressive loss of retinal photoreceptor cells, can be inherited in all modes of inheritance: autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), and mitochondrial. Based on the pattern of inheritance of the dystrophy, retinal gene therapy has 2 main strategies. AR, XL, and AD IRDs with haploinsufficiency can be treated by inserting a functional copy of the gene using either viral or nonviral vectors (gene augmentation)...
January 28, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30676837/retrospective-medical-record-review-to-describe-use-of-repository-corticotropin-injection-among-patients-with-uveitis-in-the-united-states
#5
Winnie W Nelson, Antonio Flavio Lima, John Kranyak, Barima Opong-Owusu, Gosia Ciepielewska, Jack R Gallagher, Kylee Heap, Susan Carroll
INTRODUCTION: Repository corticotropin injection (RCI) has immune-modulatory and anti-inflammatory effects and is approved for multiple indications, including severe and acute chronic allergic and inflammatory processes involving the eye and adnexa. This study describes patient characteristics, treatment patterns, and physicians' assessments of patients with uveitis treated with RCI. METHODS: This was a retrospective medical record review of US patients. Eligible patients had a diagnosis of uveitis, received RCI in the past 12 months, and had completed or were receiving RCI treatment at the time of data collection...
January 24, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30676206/eyes-on-new-product-development
#6
Gary D Novack
No abstract text is available yet for this article.
January 24, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30668279/conbercept-and-ranibizumab-pretreatments-in-vitrectomy-with-silicone-oil-infusion-for-severe-diabetic-retinopathy
#7
Kai-Bo Yang, Han Zhang, Si-Jia Li, Jiao-Jiao Cao, Lu-Na Cheng, Yu-Xi Lin, Zhe-Chen Tian, Jun Li, Feng Gu, Zhe-Li Liu
PURPOSE: We compared the efficacies of intravitreal ranibizumab (IVR) and intravitreal conbercept (IVC) as the adjuvant pretreatments for vitrectomy with silicone oil infusion for tractional retinal detachment (TRD) secondary to proliferative diabetic retinopathy. METHODS: This retrospective study comprised 74 patients (79 eyes) who underwent vitrectomy with silicone oil tamponade for diabetic TRD. They received IVC (37 eyes) or IVR (42 eyes) at standard doses 3-5 days preoperatively and were followed up for ∼6 months...
January 22, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30615539/co-delivery-of-timolol-and-brimonidine-with-a-polymer-thin-film-intraocular-device
#8
Karen E Samy, Yiqi Cao, Jean Kim, Nina Rosa Konichi da Silva, Audrey Phone, Michele M Bloomer, Robert B Bhisitkul, Tejal A Desai
PURPOSE: We developed a polycaprolactone (PCL) co-delivery implant that achieves zero-order release of 2 ocular hypotensive agents, timolol maleate and brimonidine tartrate. We also demonstrate intraocular pressure (IOP)-lowering effects of the implant for 3 months in vivo. METHODS: Two PCL thin-film compartments were attached to form a V-shaped co-delivery device using film thicknesses of ∼40 and 20 μm for timolol and brimonidine compartments, respectively...
January 7, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30614750/novel-triamcinolone-acetonide-loaded-liposomes-topical-formulation-for-the-treatment-of-cystoid-macular-edema-after-cataract-surgery-a-pilot-study
#9
Alejandro Gonzalez-De la Rosa, Jose Navarro-Partida, Juan Carlos Altamirano-Vallejo, Ada Gabriela Hernandez-Gamez, Jesus Javier Garcia-Bañuelos, Juan Armendariz-Borunda, Arturo Santos
PURPOSE: To report tolerability, safety, and efficacy of a topical triamcinolone acetonide-loaded liposomes formulation (TA-LF) in targeting the macular area in patients with refractory pseudophakic cystoid macular edema (PCME). METHODS: For tolerability, safety and efficacy evaluation, 12 eyes of 12 patients with refractory PCME were exposed to one drop of TA-LF (TA at 0.2%) every 2 h for 90 days or until best-corrected visual acuity (BCVA) was achieved. Intraocular pressure (IOP), slit lamp examination, and central foveal thickness (CFT) were analyzed at every visit...
January 7, 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30596540/celastrol-ameliorates-inflammation-in-human-retinal-pigment-epithelial-cells-by-suppressing-nf-%C3%AE%C2%BAb-signaling
#10
Jingyue Zhang, Kewen Zhou, Xinyu Zhang, Yeqi Zhou, Zhen Li, Fu Shang
PURPOSE: Celastrol is a triterpenoid quinine methide that exerts important biological effects on a variety of disease models. In this study, we aim to assess the ability of celastrol to inhibit lipopolysaccharide (LPS)-induced inflammation in retinal pigment epithelial (RPE) cells. METHODS: Primary cultures of human RPE (HRPE) cells and ARPE-19 cell lines were treated with celastrol alone or in combination with LPS. The cytotoxic effect of celastrol on RPE cells was determined by the CCK-8 assay...
December 31, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30589605/the-in-vitro-evaluation-of-povidone-iodine-against-multiple-ocular-adenoviral-types
#11
Kathleen A Yates, Robert M Q Shanks, Regis P Kowalski, Eric G Romanowski
PURPOSE: Povidone-iodine (P-I) is being touted as a topical antiviral treatment for eye infections caused by adenovirus (Ad). This study evaluated the in vitro antiviral activity of the several P-I concentrations previously used in clinical studies against multiple ocular Ad types commonly associated with eye infections. METHODS: The antiviral activity of four concentrations of P-I was compared to vehicle for seven types of Ad after incubating the P-I with Ad at 33°C for various lengths of time...
December 27, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30566384/eyes-on-new-product-development
#12
Gary D Novack
No abstract text is available yet for this article.
December 19, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30562134/pilot-study-of-the-safety-and-tolerability-of-a-subconjunctival-penciclovir-implant-in-cats-experimentally-infected-with-herpesvirus
#13
Jill C Covert, Sara M Thomasy, Helen Kado-Fong, Leslie N Kon, Philip H Kass, Christopher M Reilly, Michael R Lappin, Barry J Margulies, David J Maggs
PURPOSE: To assess safety and tolerability of a subconjunctival penciclovir implant in cats infected with feline herpesvirus type 1 (FHV-1). METHODS: Subconjunctival blank (n = 4 cats) or penciclovir-impregnated (n = 6) silicone implants were placed bilaterally in 10 normal, FHV-1-naive cats 7-8 days before viral inoculation. Outcomes included disease score, FHV-1 serology, conjunctival viral load, Schirmer tear tests (STT), tear film break-up times (TFBUTs), conjunctival histology, goblet cell density (GCD), body weight, tear and plasma penciclovir concentration, and corneal ulcer evaluation...
December 18, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30547709/in-vivo-choroidal-neovascularization-and-macrophage-studies-provide-further-evidence-for-a-broad-role-of-prostacyclin-in-angiogenesis
#14
David F Woodward, Jenny W Wang, Ming Ni, Alex J Bauer, Neil J Poloso
PURPOSE: The purpose of these studies was (1) to investigate the ability of human M1 phenotype macrophages to secrete vascular endothelial growth factor (VEGF) and the influence of prostacyclin receptor (IP) stimulation (2) to evaluate the contribution of the proangiogenic prostanoid prostacyclin to experimental choroidal neovascularization Methods: Human macrophages derived from primary blood mononuclear cells were functionally biased toward the M1 phenotype by using tumor necrosis factor α (TNFα)...
December 14, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30489200/preclinical-evaluation-of-a-new-hydroxypropyl-guar-phospholipid-nanoemulsion-based-artificial-tear-formulation-in-models-of-corneal-epithelium
#15
Rekha Rangarajan, Howard Ketelson
PURPOSE: To evaluate the effect of hydroxypropyl-guar anionic phospholipid nanoemulsion (HP-guar nanoemulsion), a new artificial tear formulation for treatment of dry eye disease (DED), in corneal epithelium models. METHODS: Cultured human corneal epithelial cells were used to assess (1) hydration protection and hydration retention protection against desiccation, and (2) cell recovery after benzalkonium chloride (BAC) damage. Corneal epithelium permeability was measured by 5,6-carboxyfluorescein (CF) uptake in intact rabbit eyes...
November 29, 2018: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30699063/re-the-efficacy-and-safety-of-the-fixed-combination-of-brinzolamide-1-and-brimonidine-0-2-in-normal-tension-glaucoma-an-18-month-retrospective-study-by-jin-and-lee-j-ocul-pharmacol-ther-34-274-279-2018
#16
Paul Y Chua, Gerry Clare, Thorfinn Leslie
No abstract text is available yet for this article.
January 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30699062/response-to-chua-et-al-re-the-efficacy-and-safety-of-the-fixed-combination-of-brinzolamide-1-and-brimonidine-0-2-in-normal-tension-glaucoma-an-18-month-retrospective-study
#17
Sang Wook Jin
No abstract text is available yet for this article.
January 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30699061/linear-polyethylenimine-dna-nanoconstruct-for-corneal-gene-delivery
#18
Jason T Rodier, Ratnakar Tripathi, Michael K Fink, Ajay Sharma, Madhuri Korampally, Shubhra Gangopadhyay, Elizabeth A Giuliano, Prashant R Sinha, Rajiv R Mohan
PURPOSE: This study investigated the efficiency and potential toxicity of a linear 22-kDa polyethylenimine (PEI)-DNA nanoconstruct for delivering genes to corneal cells and the effects of PEI nitrogen-to-DNA phosphate (N:P) ratio on gene transfer efficiency in vitro and in vivo. METHODS: A gel retardation assay, zeta potential measurement, bright-field microscopy, transfection with green fluorescent protein (GFP), immunofluorescence, and enzyme-linked immunosorbent assay (ELISA) were used to characterize the physicochemical and biological properties and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH), and reactive oxygen species (ROS) assay for cytotoxicity of the linear PEI-DNA nanoconstruct using in vitro cultured primary human corneal fibroblast and in vivo mouse models...
January 2019: Journal of Ocular Pharmacology and Therapeutics
https://read.qxmd.com/read/30699060/correction-to-efficacy-and-safety-of-0-6-pazufloxacin-ophthalmic-solution-versus-moxifloxacin-0-5-and-gatifloxacin-0-3-in-subjects-with-bacterial-conjunctivitis-a-randomized-clinical-trial-by-baiza-dur%C3%A3-n-l-olvera-monta%C3%A3-o-o-mercado-sesma-a-r-and-oregon-miranda
#19
https://read.qxmd.com/read/30412448/double-masked-randomized-phase-2-evaluation-of-abicipar-pegol-an-anti-vegf-darpin-therapeutic-in-neovascular-age-related-macular-degeneration
#20
David Callanan, Derek Kunimoto, Raj K Maturi, Sunil S Patel, Giovanni Staurenghi, Sebastian Wolf, Janet K Cheetham, Thomas C Hohman, Kimmie Kim, Francisco J López, Susan Schneider
PURPOSE: To evaluate safety and efficacy of the vascular endothelial growth factor binding protein abicipar pegol (abicipar) versus ranibizumab for neovascular age-related macular degeneration. METHODS: Phase 2, multicenter, randomized, double-masked comparison (REACH study, stage 3). Patients (n = 64) received intravitreal injections of abicipar 1 mg or 2 mg at baseline, week 4, and week 8 (3 injections) or ranibizumab 0.5 mg at baseline and monthly (5 injections)...
November 9, 2018: Journal of Ocular Pharmacology and Therapeutics
journal
journal
32321
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"